Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5300-0.1200 (-7.27%)
At close: 04:00PM EDT
1.5200 -0.01 (-0.65%)
After hours: 04:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6500
Open1.6100
Bid1.5200 x 27000
Ask1.5700 x 34100
Day's Range1.5100 - 1.6200
52 Week Range1.4800 - 6.7900
Volume4,430,866
Avg. Volume4,629,830
Market Cap392.951M
Beta (5Y Monthly)1.13
PE Ratio (TTM)85.00
EPS (TTM)0.0180
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
  • Zacks

    Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

    Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Agenus Corporate Update and First Quarter 2022 Financial Report

    Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for the fi

  • GlobeNewswire

    Agenus to Provide Corporate Update and First Quarter 2022 Financial Report

    Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ETLEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its first quarter 2022 financial results before the market opens on Tuesday, May 10, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the

Advertisement
Advertisement